They also follow a recent partnership with Costco, which began offering low-dose Ozempic and Wegovy for $499 per month out of ...

Constipation is a common but manageable side effect of Ozempic, a medication for diabetes and weight loss. It often occurs in ...

Until the end of March, Novo Nordisk will let people with prescriptions buy the first two doses of the drugs for $199 a month ...

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

Viking Therapeutics completes enrollment in phase 3 VANQUISH-1 trial of VK2735 to treat metabolic disorders: San Diego Thursday, November 20, 2025, 13:00 Hrs [IST] Viking Therapeu ...

Concurrently, Viking is conducting the Phase 3 VANQUISH-2 study of subcutaneous VK2735 in patients with type 2 diabetes who have obesity or are overweight. That trial is currently enrolling patients, ...

Shares of Vanda Pharmaceuticals VNDA rallied 21.6% on Tuesday after the company reported positive top-line results from a mid ...

Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest in VK2735 ...

Novo Nordisk offers Wegovy and Ozempic at $199/month for new self-pay patients, valid for the first two months until March 31, 2026. The promotion aligns with a national agreement to improve access ...

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

Oral semaglutide—the ingredient in obesity and diabetes drugs Ozempic and Wegovy—didn’t slow Alzheimer’s disease in two ...